Construction of anticancer drug incorporated aptamer-functionalized cationic β-lactoglobulin: induction of cell cycle arrest and apoptosis in colorectal cancer DOI
Zhipeng Zhang, Tianran Zhang, Zimeng Li

и другие.

Journal of Biomaterials Science Polymer Edition, Год журнала: 2024, Номер unknown, С. 1 - 20

Опубликована: Окт. 16, 2024

Nanoscale drug delivery systems that are both multifunctional and targeted have been developed using proteins as a basis, thanks to their attractive biomacromolecule properties. A novel nanocarrier, aptamer (AS1411)-conjugated β-lactoglobulin/poly-l-lysine (BLG/Ap/PL) nanoparticles, was in this study. To unique formulation, the as-prepared nanocarrier blends distinctive features of an chemotherapeutic targeting agent with those protein nanocarriers. By loading cabazitaxel (CTX) onto nanocarriers, therapeutic potential BLG/Ap/PL could be demonstrated. The CTX-loaded (CTX@BLG/Ap/PL) showed regulated release profile acidic milieu, which improve efficacy cancer cells high encapsulation up 93%. However, compared free CTX, CTX@BLG/Ap/PL killed colorectal HCT116 higher at 24 48 h. Further investigation confirms apoptosis by acridine orange ethidium bromide (AO/EB), DAPI staining morphological changes, chromatin condensation, membrane blebbing treated cell through flow cytometry displayed percentages apoptosis. Cell cycle analysis revealed induced sub-G1 G2/M phase (apoptosis) Annexin V/propidium iodide (PI) confirmed induces cells. Overall, study proved had several advantages over drugs promise solution clinical problems associated antitumor systems.

Язык: Английский

RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy DOI
Mehdi Sanati, Amir R. Afshari, Samaneh Aminyavari

и другие.

Journal of Drug Delivery Science and Technology, Год журнала: 2023, Номер 84, С. 104562 - 104562

Опубликована: Май 13, 2023

Язык: Английский

Процитировано

27

Liposome-integrated hydrogel hybrids: Promising platforms for cancer therapy and tissue regeneration DOI Creative Commons
Mehdi Sanati, Saber Amin Yavari

Journal of Controlled Release, Год журнала: 2024, Номер 368, С. 703 - 727

Опубликована: Март 19, 2024

Drug delivery platforms have gracefully emerged as an indispensable component of novel cancer chemotherapy, bestowing targeted drug distribution, elevating therapeutic effects, and reducing the burden unwanted side effects. In this context, hybrid systems artfully harnessing virtues liposomes hydrogels bring remarkable benefits, especially for localized therapy, including intensified stability, excellent amenability to hydrophobic hydrophilic medications, controlled liberation behavior, appropriate mucoadhesion mucopenetration shift. Moreover, three-dimensional biocompatible liposome-integrated hydrogel networks attracted unprecedented interest in tissue regeneration, given their tunable architecture physicochemical properties, well enhanced mechanical support. This review elucidates presents cutting-edge developments recruiting treatment regeneration.

Язык: Английский

Процитировано

16

Advances in liposome-based delivery of RNA therapeutics for cancer treatment DOI
Mehdi Sanati, Amir R. Afshari,

Seyed Sajad Ahmadi

и другие.

Progress in molecular biology and translational science, Год журнала: 2024, Номер unknown, С. 177 - 218

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

10

Aptamers combined with immune checkpoints for cancer detection and targeted therapy: A review DOI
Yihan Li, Weidong Liu,

Hongjuan Xu

и другие.

International Journal of Biological Macromolecules, Год журнала: 2024, Номер 262, С. 130032 - 130032

Опубликована: Фев. 9, 2024

Язык: Английский

Процитировано

7

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges DOI Open Access
Wojciech Szymanowski, A. Szymanowska, Anna Bielawska

и другие.

Cancers, Год журнала: 2023, Номер 15(21), С. 5300 - 5300

Опубликована: Ноя. 6, 2023

Ovarian cancer (OC) is the most common lethal gynecologic cause of death in women worldwide, with a high mortality rate and increasing incidence. Despite advancements treatment, OC patients still die from their disease due to late-stage diagnosis, lack effective diagnostic methods, relapses. Aptamers, synthetic, short single-stranded oligonucleotides, have emerged as promising anticancer therapeutics. Their ability selectively bind target molecules, including cancer-related proteins receptors, has revolutionized drug discovery biomarker identification. Aptamers offer unique insights into molecular pathways involved development progression. Moreover, they show immense potential delivery systems, enabling targeted therapeutic agents cells while minimizing off-target effects reducing systemic toxicity. In context OC, integration aptamers non-coding RNAs (ncRNAs) presents an opportunity for precise efficient gene targeting. Additionally, conjugation nanoparticles allows accurate ncRNAs specific cells, tissues, or organs. this review, we will summarize use challenges associated alone aptamer–ncRNA conjugates, nanoparticles, multivalent aptamer-based therapeutics treatment OC.

Язык: Английский

Процитировано

14

αvβ3 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment DOI
Prashant Kesharwani,

Jyoti Chandra,

Shahid Karim

и другие.

Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер 96, С. 105663 - 105663

Опубликована: Апрель 16, 2024

Язык: Английский

Процитировано

4

A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules DOI
Amir R. Afshari, Mehdi Sanati, Samaneh Aminyavari

и другие.

Inflammopharmacology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 16, 2025

Язык: Английский

Процитировано

0

Wolf in Sheep’s Clothing: Taming Cancer’s Resistance with Human Serum Albumin? DOI Creative Commons
Iga Stukan, Anna Żuk,

Kamila Pukacka

и другие.

International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 3493 - 3525

Опубликована: Март 1, 2025

Human serum albumin (HSA) has emerged as a promising carrier for nanodrug delivery, offering unique structural properties that can be engineered to overcome key challenges in cancer treatment, especially resistance chemotherapy. This review focuses on the cellular uptake of albumin-based nanoparticles and modifications enhance their ability bypass mechanisms, particularly multidrug type 1 (MDR1), by improving targeting cells. In our approach, we integrate chemical albumin, its interactions with cells, surface delivery systems enable those related MDR1, precisely target receptors cells improve treatment efficacy. We discuss while well-established such gp60 gp18/30 are crucial transcytosis, biology remains underexplored, limiting translational potential. Additionally, explore potential emerging targets, cluster differentiation 44 (CD44), (CD36) transferrin receptor TfR1, well advantages using dimeric forms (dHSA) further resistant Drawing from clinical examples, including success albumin-bound paclitaxel (Abraxane) new formulations like Pazenir Fyarro (for Sirolimus), identify gaps current knowledge propose strategies optimize systems. conclusion, nanoparticles, when tailored appropriate modifications, have By enhancing albumin's efficiently deliver therapeutic agents, these carriers represent approach addressing one oncology's most persistent challenges, substantial outcomes.

Язык: Английский

Процитировано

0

Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers DOI
Mehdi Sanati, Christian G. Figueroa‐Espada, Emily L. Han

и другие.

ACS Nano, Год журнала: 2024, Номер unknown

Опубликована: Дек. 12, 2024

Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as gene therapy modality to sensitize cells chemotherapy. However, use of RNAi, specifically small-interfering (siRNA), is hindered by biological barriers that limit its intracellular delivery. Nanoparticles can overcome these protecting siRNA in physiological environments and facilitating delivery cells. In this review, we discuss development nanomaterials for therapy, current challenges, future perspectives their implementation chemoresistance.

Язык: Английский

Процитировано

3

Harnessing MUC1 aptamer-targeted nanoparticles for precision medicine in breast cancer DOI
Mohammad Sameer Khan, Garima Gupta,

Abdulrhman Alsayari

и другие.

International Journal of Pharmaceutics, Год журнала: 2025, Номер 678, С. 125721 - 125721

Опубликована: Май 11, 2025

Язык: Английский

Процитировано

0